What's Happening?
A recent study published in the Southern Economic Journal indicates that corporate mergers can lead to cost efficiencies for the merging companies without necessarily translating into lower prices for consumers. The research, which examined the 2019 merger between
pharmaceutical giants GSK and Pfizer's consumer healthcare businesses, found that while the combined entity became cheaper to operate, these savings were not consistently passed on to shoppers. In some instances, prices for certain products, including those from a major rival, increased. Specifically, the study observed that the estimated cost of supplying Pfizer products decreased by 9.43%, and their prices dropped by 6.57%. However, GSK's prices rose by an estimated 3.25%, and Sanofi, a significant international competitor, increased its prices by 8.55%. Prices from a local manufacturer, Unilab, remained largely unchanged. Lead author Prof. Farasat Bokhari from Loughborough University noted that while companies often argue that mergers create efficiencies, the reality can be more complex, suggesting that fewer independent competitors might facilitate price coordination without explicit agreements.
Why It's Important?
This research carries significant implications for U.S. competition authorities and regulatory bodies tasked with approving corporate mergers. The findings challenge the conventional argument that mergers, by creating efficiencies, will inherently benefit consumers through lower prices. Instead, the study suggests that cost savings from mergers might primarily benefit the companies themselves, potentially leading to increased profits without a corresponding reduction in consumer costs. This could result in a less competitive market landscape where consumers pay more due to reduced competition and easier price coordination among remaining players. For industries like pharmaceuticals, where product prices directly impact public health and household budgets, this dynamic is particularly critical. The study highlights a potential gap in current merger review processes, urging authorities to consider not only efficiency gains but also the likelihood of increased market coordination and its adverse effects on consumer pricing.
What's Next?
The findings are expected to prompt competition authorities to re-evaluate their criteria for approving future mergers. Regulators may need to adopt a more stringent approach, scrutinizing not just the potential for cost efficiencies but also the broader market impact on pricing and competition. This could lead to more detailed analyses of how mergers might enable tacit collusion or reduce competitive pressure, potentially resulting in more conditions placed on merger approvals or even outright rejections if consumer welfare is deemed to be at risk. Companies planning mergers may also face increased pressure to demonstrate how their proposed combinations will genuinely benefit consumers, beyond just internal cost savings. The study's insights could influence policy discussions around antitrust enforcement and market concentration in various sectors.
Beyond the Headlines
The study delves into the subtle yet powerful mechanism of 'coordinated effects' in post-merger markets. It suggests that even without explicit agreements, a reduction in the number of independent competitors can make it easier for remaining companies to align their pricing strategies, leading to higher prices than would exist under more robust competition. This highlights a critical ethical dimension: while mergers can be financially advantageous for corporations and their shareholders, the benefits may not trickle down to the public. The long-term societal impact could include reduced innovation, less consumer choice, and a greater burden on consumers, particularly in essential sectors like healthcare. This research underscores the ongoing tension between corporate growth strategies and the public interest, urging a re-examination of the fundamental assumptions underpinning merger regulations to ensure that market consolidation does not inadvertently harm consumers.
